These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36991453)

  • 21. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder.
    Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV
    J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
    Evans EA; Yoo C; Huang D; Saxon AJ; Hser YI
    J Subst Abuse Treat; 2019 Nov; 106():19-28. PubMed ID: 31540607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
    Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
    Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.
    Ghosh A; Shaktan A; Basu D; Bn S; Naik SS; Mattoo SK
    J Psychoactive Drugs; 2024; 56(3):364-372. PubMed ID: 37318513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
    Worley MJ; Shoptaw SJ; Bickel WK; Ling W
    Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
    Sullivan JG; Webster L
    Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
    Balhara YPS; Singh S; Sarkar S
    Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
    Hassan AN; Bozinoff N; Jutras-Aswad D; Socias ME; Stewart SH; Lim R; Le Foll B;
    J Addict Med; 2023 Jan-Feb 01; 17(1):e49-e56. PubMed ID: 35916430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.